Journals / Medicine Science / 2021 / Cilt: 10 - Sayı: 4

Is urotensin 2 levels related to disease progression in acromegaly

Pages
1534–1537
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Serum urotensin-2 stage was lower in acromegaly patients compared to the healthy group (control) and this variation was not statistically significant.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The study aimed to compare serum Urotensin-2 stages in the patients having active acromegaly with healthy individuals and to reveal and discuss the possible effects of UII on vascular changes in acromegaly patients.
📊
Key Findings & Data:In this prospective, serum urotensin stages of 30 active acromegalic patients who are followed up in the experienced adult endocrinology center were compared with the serum urotensin stages of 30 healthy volunteers.
💡
Conclusion & Impact:Serum urotensin-2 stage was lower in acromegaly patients compared to the healthy group (control) and this variation was not statistically significant.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The study aimed to compare serum Urotensin-2 stages in the patients having active acromegaly with healthy individuals and to reveal and discuss the possible effects of UII on vascular changes in acromegaly patients. In this prospective, serum urotensin stages of 30 active acromegalic patients who are followed up in the experienced adult endocrinology center were compared with the serum urotensin stages of 30 healthy volunteers. Patients' IGF-1 along with GH were carefully measured by ECLIA method, and serum urotensin stages, by ELISA method. There was no variation between two groups comparing there age (p = 0.43). Patient group, mean GH was 6.60 ng / mL with mean IGF-1 stage of 355.2 ng / mL. The mean urotensin stage was 3.62±2.27 pmol / L in the acromegaly group, 4.82±2.87 pmol / L in the healthy control group. There was no significant positive correlation of urotensin with IGF-1 stages (r = 0.11, p>0.05). Similarly, the results did not display significant positive correlation urotensin stage with GH (r = 0.13, p>0.05). Serum urotensin-2 stage was lower in acromegaly patients compared to the healthy group (control) and this variation was not statistically significant.

🔖

Cite This Article

Kilinc, F., Evren, B., Ozdemir, F. A., Gozel, N., Pekkolay, Z., Cakmak, E. (2022). Is urotensin 2 levels related to disease progression in acromegaly. Medicine Science, Cilt: 10 - Sayı: 4, 1534–1537. https://ajindex.com/articles/579620

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Katznelson L, Laws ER Jr, Melmed S, et al. Endocrine society acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:3933-51
  2. Colao A, Pivonello R, Grasso LF, et al. Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study Eur J Endocrinol. 2011;165:713-21
  3. Colao A, Vitale G, Pivonello R, et al. Lombardi G. The heart: an end-organ of GH action. Eur J Endocrinol. 2004;151:93-101
  4. Dutta P, Das S, Bhansali A, et al. Congestive heart failure in acromegaly: A review of 6 cases. Indian J Endocrinol Metab. 2012;16:987-90
  5. Molitch ME. Clinical manifestations of acromegaly. Endocrinol Metab Clin North Am. 1992;21:597-614
  6. Gozu HI, Oztas D, Guleryuzlu Y, et al.Evaluation of cardiovascular parameters in acromegalic patients. Turk J Endocrinol Metab. 2007;11:1-6
  7. Vaudry H, Leprince J, Chatenet D, et al. International union of basic and clinical pharmacology. XCII. Urotensin II, urotensin II-related peptide, and their receptor: from structure to function. Pharmacol Rev. 2015;67:214-58
  8. Peng H, Zhang M, Cai X, et al. Association between human urotensin II and essential hypertension-a 1:1 matched case-control study. PLoS One. 2013; 8:1-6
  9. Buyukhatipoglu H, Buyukaslan H, Pehlivan Y, et al. Increased urotensin- II activity in patients with Raynaud’s phenomenon and systemic lupus erythematosus. Int J Rheum Dis. 2011;143:276-81
  10. Demirpence M, Guler A, Yilmaz H,, et al. Is elevated urotensin II level a predictor for increased cardiovascular risk in subjects with acromegaly? J Endocrinol Invest. 2019;42:207-15
  11. Ong KL, Lam KS, Cheung BM Urotensin II: its function in health and its function in disease. Cardiovasc Drugs Ther. 2005;19:65-75
  12. Gruson D, Rousseau MF, Ketelslegers J-M,et al. Raised plasma urotensin ii in type 2 diabetes patients is associated with the metabolic syndrome phenotype. J Clin Hypertension. 2010;12:653-60
  13. McDonald J, Batuwangala M, Lamber DG. Role of urotensin II and its receptor in health and disease. J Anesth. 2007;21:378-89
  14. Ong KL, Lam KS, Cheung BM. Urotensin II: its function in health and its function in disease. Cardiovasc Drugs Ther. 2005;19:65-75
  15. Gozel N, Oral K, Ozdemir FA, et al. An investigation of saliva and plasma levels of urotensin2 in recently diagnosed type 2 Diabetes mellitus patients on metformin treatment. Endokrynologia Polska. 2020;246-254:1-6
  16. Bousette N, Patel L, Douglas SA, et al.